Foghorn Therapeutics earnings were -$80.4M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest FHTX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$18.8M, down 3.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, FHTX reported annual earnings of -$86.6M, with -12% growth.
Foghorn Therapeutics Earnings Reports & History FAQ
What were Foghorn Therapeutics's earnings last quarter?
On FHTX's earnings call on Invalid Date, Foghorn Therapeutics (NASDAQ: FHTX) reported Q1 2025 earnings per share (EPS) of -$0.30, up 49.15% year over year. Total FHTX earnings for the quarter were -$18.83 million. In the same quarter last year, Foghorn Therapeutics's earnings per share (EPS) was -$0.59.
Is Foghorn Therapeutics profitable or losing money?
As of the last Foghorn Therapeutics earnings report, Foghorn Therapeutics is currently losing money. Foghorn Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$80.44 million, a 13.46% decrease year over year.
What was FHTX's earnings growth in the past year?
As of Foghorn Therapeutics's earnings date in Invalid Date, Foghorn Therapeutics's earnings has grown year over year. FHTX earnings in the past year totalled -$80.44 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.